LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Verve Therapeutics Inc

Open

11.28 0.71

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.2

Max

11.28

Schlüsselkennzahlen

By Trading Economics

Einkommen

19M

-31M

Verkäufe

20M

33M

EPS

-0.35

Gewinnspanne

-94.108

Angestellte

274

EBITDA

19M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+34.34% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

604M

992M

Vorheriger Eröffnungskurs

10.57

Vorheriger Schlusskurs

11.28

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Verve Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Juni 2025, 11:56 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17. Juni 2025, 14:02 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17. Juni 2025, 12:12 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17. Juni 2025, 11:01 UTC

Akquisitionen, Fusionen, Übernahmen

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17. Juni 2025, 10:47 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17. Juni 2025, 10:47 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17. Juni 2025, 10:46 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17. Juni 2025, 10:45 UTC

Akquisitionen, Fusionen, Übernahmen

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17. Juni 2025, 09:33 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Peer-Vergleich

Kursveränderung

Verve Therapeutics Inc Prognose

Kursziel

By TipRanks

34.34% Vorteil

12-Monats-Prognose

Durchschnitt 15.06 USD  34.34%

Hoch 24 USD

Tief 11 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Verve Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

4

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

4.1501 / 5.16Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.